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ABSTRACT
Objectives: Coronary artery disease (CAD), as the leading cause of death,
poses a huge economic burden on health-care systems. We used a multi-
marker approach to explore discriminative abilities of several lipid,
inﬂammatory, and oxidative stress/antioxidative defense markers as CAD
predictors. We assessed their cost-effectiveness compared with the
Framingham risk score (FRS).
Methods: Using a decision model, we evaluated the costs, accuracy, and
cost-effectiveness of each model. The FRS was used as the baseline model.
Other models were formed with the consecutive addition of selected
markers: apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), apolipo-
protein (a) [apo(a)] isoform, lipoprotein (a), high-sensitivity C-reactive
protein, malondialdehyde, superoxide dismutase (SOD), sulfhydryl, and
superoxide anion (O2-). A best-case model was formed from a combina-
tion of diagnostic markers to yield the best patient stratiﬁcation algorithm.
All models were assessed by their predictive probabilities using receiver
operating characteristic curves. To accomplish our goals, we recruited 188
CAD patients (veriﬁed by coronary angiography) and 197 asymptomatic
CAD-free subjects for comparison. The analysis was performed from a
third-party payer perspective.
Results: Only two strategies had outstanding discriminative abilities: the
best-case model (FRS, SOD, and O2-) and FRS plus SOD with area under
the curve (AUC) values of 0.924 and 0.906, respectively. The cost-
effectiveness ratio varied between €593 per AUC for the baseline model to
€2425 per AUC for FRS plus apo(a) isoform. Strategies involving oxidative
stress/antioxidative defense markers were more cost-effective than strate-
gies involving lipid or inﬂammatory markers. All results were robust.
Conclusion: Our results support the feasibility of a multimarker approach
for CAD screening. The introduction of oxidative stress/antioxida-
tive defense markers in the clinical laboratory would be convenient and
cost-effective.
Keywords: coronary artery disease, cost-effectiveness, multimarker
approach, risk prediction.
Introduction
Coronary artery disease (CAD) is the major cause of death world-
wide [1]. CAD mortality in Eastern European countries is much
higher than the European average as it reaches a value of 650 of
100,000 in some countries [2]. The direct health-care cost of CAD
in the European Union was just under €23 billion in 2003 of
which inpatient expenditure represented 62% of the total costs.
CAD is estimated to represent one quarter of the overall cost of
cardiovascular disease management and treatment [3].
Atherosclerosis is the underlying cause in most CAD cases
with its typical clinical manifestations being myocardial infarc-
tion, angina, and stroke. Atherosclerosis is a complex disease
caused by a variety of risk factors such as dyslipidemia, inﬂam-
mation, and/or oxidative stress, and many individual biomarkers
have been used for CAD risk assessment. The association of total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-c),
and high-density lipoprotein cholesterol (HDL-c) levels with
coronary diseases has been proven, and such parameters are
commonly measured in current diagnostic practice. Other lipid-
related measurements such as apolipoprotein A-I (apoA-I), apo-
lipoprotein B (apoB) [4], apolipoprotein (a) [apo(a)] isoform, or
lipoprotein (a) (Lp(a)) [5,6] have been correlated with coronary
diseases and may add more predictive power to more commonly
used lipid markers. The prognostic utility of high-sensitivity
C-reactive protein (hs-CRP) and its ability to predict future
coronary events has been reported in clinical studies [7–11].
Markers of oxidative stress and antioxidative defense risk
parameters, mainly malondialdehyde (MDA), superoxide anion
(O2-), superoxide dismutase (SOD), and sulfhydryl (SH) groups,
are closely related to endothelial dysfunction, which as a function
of time progresses to symptomatic CAD [12–15]. Nevertheless,
none of the aforementioned risk factors used by them as a single
biomarker is able to predict CAD with sufﬁcient accuracy. There-
fore, measurement of multiple biomarkers may be an effective
strategy to improve prediction of cardiovascular events [16,17].
The Framingham risk score (FRS) is nowadays widely used as
a tool for coronary risk stratiﬁcation. Several predictors are
included in the FRS: age, gender, TC, HDL-c, blood pressure,
antihypertensive therapy, and cigarette smoking. Nevertheless,
sensitivity and speciﬁcity of the FRS do not exceed 70% and
82%, respectively, if all the risk factors are included [18]. Limi-
tations of the FRS (narrow section of the population) restricts
FRS applicability [19,20] and poses a challenge to researchers in
predicting the risk for coronary events. One of the ways to
overcome this limitation is the introduction of additional bio-
logical markers that enhance FRS predictive power.
Bearing in mind that CAD is a global problem, it is also very
important that laboratory markers, especially those used for
screening and diagnostic purposes, are cost-effective. The results
of economic evaluation of lipid and/or inﬂammatory markers
have been reported in a limited number of studies [21–23].
Nevertheless, so far, there have been no reports regarding cost-
effectiveness of oxidative stress and antioxidative markers for
CAD risk prediction. In our present study, we used a multi-
marker approach, ﬁrst, to explore the abilities of several lipid,
inﬂammatory, and oxidative stress/antioxidative defense markers
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to enhance FRS prediction of cardiovascular risk. Second, we
analyzed the cost-effectiveness of adding different individual
markers to the FRS to identify the most cost-effective strategy for
CAD prediction.
Materials and Methods
Study Participants
We recruited 188 CAD patients (122 males and 66 females, mean
age 56.0  9.08 years) from the Institute of Cardiovascular
Disease, Clinical Centre of Serbia, Belgrade, and 197 asymptom-
atic CAD-free subjects (113 males and 84 females, mean age
55.7  10.37 years) who attended a regular annual medical
checkup at various public health centers in Belgrade for compari-
son purposes. The presence of clinically signiﬁcant CAD (stenosis
50%) in at least one of the three major coronary vessels (the left
main or the left anterior descending artery, the left circumﬂex
artery, and right coronary artery) was veriﬁed by coronary angiog-
raphy. Two cardiologists unaware that the patients were enrolled
in the study reviewed all the angiograms as a validation procedure
for correct diagnosis. For the purpose of the current study, patients
with coronary artery stenosis of subclinical signiﬁcance (<50%)
were not included. The absence of clinically signiﬁcant CAD in the
group of healthy controls was veriﬁed by normal electrocardio-
gram (ECG) and exercise test results, but subclinical stenosis could
not be ruled out.
All enrolled study participants completed a questionnaire that
contained numerous risk-related issues. The following factors
were recorded for all participants: body mass index, smoking
habits, and systolic and diastolic blood pressure (SBP and DBP,
respectively). Hypertension was deﬁned in subjects with SBP
140 mmHg, a DBP of 90 mmHg, or being on antihyperten-
sive medication. We excluded subjects with a history of recent
clinical infection or hs-CRP concentration >10 mg/L; concurrent
major renal, hepatic, or malignant disease; surgery; or major
trauma during the month prior to study entry. Diabetic patients
(patients with a fasting glucose level 7.0 mmol/L or patients
who were receiving oral hypoglycemic agents or insulin medica-
tion) and patients receiving any antihyperlipidemic medication
were also excluded from the study.
All patients gave informed consent before their enrolment in
the study. The study was planned according to the ethical guide-
lines following the Declaration of Helsinki. The Ethics Commit-
tee for Clinical Research at the Faculty of Pharmacy approved
our study protocol.
Design
The National Cholesterol Education Program Adult Treatment
Panel III guidelines recommend calculation of the FRS for car-
diovascular risk assessment. The baseline model included FRS
and calculation of LDL-c because the concentration of LDL-c is
needed for adequate monitoring and assessment of therapy. For
the LDL-c calculation, assessment of triglycerides (TG) is
required because of that fact it is incorporated into the baseline
model. Other models were devised with the consecutive addition
of selected markers: apoA-I, apoB, apo(a) phenotype, Lp(a),
hs-CRP, MDA, SOD, SH, and O2- to the baseline model. A
best-case model was formed according to the combination of
diagnostic markers providing the best capabilities for patient
stratiﬁcation. The design is given in Figure 1.
Diagnostic Analytical Methods
Peripheral venous blood (obtained from all individuals after
overnight fasting) was drawn into collection tubes containing
heparin. Plasma was separated, and multiple aliquots of each
sample were stored at -80°C until analysis. The samples were
thawed immediately before analyses. For MDA determination,
butylated hydroxytoluene (0.05% w/v) was immediately added
to the plasma, and the mixture was stored at -80°C until analy-
sis. O2- was measured in fresh plasma samples. All the assays
were performed blindly.
Lipid status parameters were measured in heparin plasma
samples. TC, HDL-c, TG, apoA-I, and apoB were assayed
by standard laboratory procedures. The concentration of
LDL-c was calculated using the Friedewald formula [24]. The
sizes of apo(a) isoforms were determined by high-resolution
sodium dodecyl sulfate agarose gel electrophoresis followed by
immunoblotting. Calibration was performed using standards
of known number of K4 repeats provided by Technoclone
(Vienna, Austria). Lp(a) was measured using immunoturbidim-
etry (BIOKIT, Barcelona, Spain). Serum hs-CRP was quantitated
using a latex-enhanced immunoturbidimetric method employing
a Quantex hs-CRP kit (BIOKIT). Plasma MDA concentration
was measured using the thiobarbituric acid-reactive substances
(TBARS) assay previously described by Girotti et al. [25].
TBARS concentrations were measured at 535 nm, and the
data were expressed as MDA equivalents using MDA-
bis(diethylacetal) (1–10 mmol/L) as a standard (Merck, Darms-
tadt, Germany). The rate of nitroblue tetrazolium reduction was
used to measure the level of O2- as described by Auclair and
Voisin [26]. The absorbance was recorded every 15 seconds
during the ﬁrst minute of the reaction. The molar absorption
coefﬁcient of 15 ¥ 103 M/cm was used. Plasma SOD activity was
measured according to a previously published method by
Misra and Fridovich [27]. The concentration of SH groups in
Figure 1 Schematic representation of the decision model. Framingham risk
score (FRS): gender, age, total cholesterol, triglycerides, high-density lipoprotein
cholesterol, calculation of low-density lipoprotein cholesterol, systolic blood
pressure, treatment for hypertension, and cigarette smoking. *FRS plus super-
oxide dismutase (SOD) plus superoxide anion (O2-): best-case model according
to logistic regression analysis. aOutput values for cost/effectiveness for each
model. apo(a), apolipoprotein (a); Lp(a), lipoprotein (a); MDA, malondialdehyde;
hs-CRP, high-sensitivity C-reactive protein; SH, sulfhydryl.
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plasma was determined using 0.2 mmol/L of 5,5′-dithiobis
(2-nitrobenzoic acid) reported by Ellman [28].
Most of the laboratory tests were measured using an ILAB
600 analyzer (Instrumentation Laboratory, Milan, Italy). Apo(a)
isoform analysis required sodium dodecyl sulfate agarose gel
electrophoresis and immunoblotting using a Submarine Electro-
phoresis Unit (Hoeffer Pharmacia Biotech, Uppsala, Sweden).
MDA was determined manually because of the various steps
required during the analysis.
Due to intraindividual variability, values for all parameters
(except for the apo(a) phenotype) were estimated as the mean of
three measurements performed at 1 to 2-week intervals. Our
laboratory performed strict internal and external quality control
procedures. Reagents for instrument calibration were supplied by
the manufacturers.
Costs
All the costs for diagnostic reagents, consumables, and labor are
summarized in Table 1. For the laboratory markers that can be
evaluated on the automated analyzer and are reimbursed by the
Republic Institute for Health Insurance (RIHI), the costs (service
fee) were derived from the RIHI price list [29]. All the costs
indicated were from 2008. Since then, the price of all the bio-
chemical markers has not changed. For the biochemical markers
not on the RIHI list but can be analyzed automatically (O2-,
SOD, and –SH), the service fee price was calculated according to
the following: cost for test reagents, specimen collection, and fee
for technical services. For example, for the O2- costs for reagents
were calculated in the following manner: For 100 samples and
sample blank preparation, the required quantities of reagents
were the following: 101 ml of the working reagents (1 mmol/L
nitroblue tetrazolium dissolved in freshly prepared phosphate
buffer of 0.05 mmol/L with the addition of 0.1 mg/ml gelatin).
For this quantity of reagents, according to the 2008 Acros
Organics catalog, the cost for O2- evaluation was 14.84 euros.
The cost of consumables for collection tubes containing heparin
with needles was calculated as an average price recognized by the
RIHI. The fee for technical service was calculated as time needed
for specimen collection and average time needed by the analyzer
to process 100 samples multiplied by the laboratory technician’s
salary. The cost of MDA and apo(a) isoform determination was
calculated as the sum of time needed for sample preparation and
manual evaluation of the markers. The cost of test reagents
included the cost of chemicals needed for reagent preparation,
calibration, standards, and controls based on 100 analyses. Costs
were calculated based on market prices from the 2008 Acros
Organics catalog of ﬁne chemicals. The average monthly salary
of a laboratory technician was obtained from the RIHI [29]. The
total cost was calculated by adding up all the expenditures of all
direct analytical and labor resources consumed. All costs are
presented in euros (the average exchange rate in 2008 was 1
euro = 81.91 RSD).
Administrative costs (e.g., electricity) were excluded from the
calculations because these costs are the same for all compared
strategies. Non-health-care costs and indirect costs were not
included in the analysis. The outcomes were analyzed from the
perspective of a third-party payer—RIHI, as the leading health-
care payer, responsible for health care of almost the entire
Serbian population (7.5 million).
For the baseline model, the costs of TC, TG, and HDL-c were
required. The cost of LDL-c (required for FRS calculation of
10-year risk) was not included as the LDL-c concentration was
calculated manually using the Friedewald formula. The costs of
other models were equal to the sum of costs for the baseline
model and costs for additionally included laboratory markers.
The effectiveness of the models as CAD predictors was evalu-
ated using receiver operating characteristic (ROC) curves with
the predictive probabilities from different logistic regression
models.
The results are presented as the cost for 100 analyses of
laboratory markers and the incremental cost-effectiveness ratio
(ICER) for each marker. The ICER is deﬁned as the difference in
cost divided by the difference in effectiveness between competing
strategies [30]. In this case, the ICER was deﬁned as incremental
cost per additional accuracy in CAD prediction, obtained by
inclusion of a new laboratory marker between the two diagnostic
models.
Statistical and Sensitivity Analysis
Multiple logistic regression analysis was used to investigate asso-
ciation between the laboratory tests (entered as continuous vari-
ables) and the presence of CAD (a categorical dependent
variable) within different models. Controls were coded with 0,
and CAD patients were coded with 1. ROC curves with predic-
tive probabilities from logistic regression models were used to
calculate the areas under the curves (AUCs) or C-index for the
baseline model and all other constructed models. We also entered
all laboratory parameters into forward stepwise logistic regres-
sion analysis to determine the best-case model. The latter only
included those variables that emerged as statistically signiﬁcant.
By using Hosmer and Lemeshow’s rule for the logistic models,
the discriminative abilities of the models were classiﬁed accord-
ing to their AUC values as poor (0.5  AUC < 0.7), acceptable
(0.7  AUC < 0.8), excellent (0.8  AUC < 0.9), or outstanding
(AUC  0.9) [31].
In addition, the jackknife technique [32] was used to assess
the impact of potentially inﬂuential outliers that might meaning-
fully alter the interpretation of model results. The stability of a
calculated AUC was conﬁrmed by comparing the calculated t
value for the jackknifed coefﬁcient with the t critical value.
All calculations were performed using Microsoft Excel,
EduStat 2.01 (2005, Alpha Omnia, Belgrade, Serbia), and
Table 1 Total costs for laboratory markers based on 100 analyses (all
costs are presented in euros, 2008 value)
Markers
Test
reagents*
Specimen
collection†
Fee for
technical
services‡
Total
cost§
Total cholesterol — — — 156.09¶
Triglycerides — — — 159.54¶
High-density
lipoprotein
cholesterol
— — — 191.10¶
Apolipoprotein A-1 — — — 528.22¶
Apolipoprotein B — — — 514.16¶
High-sensitivity
C-reactive
protein
— — — 632.67¶
Lipoprotein (a) — — — 260.33¶
Apolipoprotein (a) isoform 622.59 28.87 103.07 754.54
Malondialdehyde 3.9 28.87 28.45 61.22
Superoxide anion 14.84 28.87 8.01 51.72
Superoxide dismutase 0.06 28.87 34.85 63.78
Sulfhydryl 0.19 28.87 7.61 36.67
*Cost for test reagents, plus costs for controls (pathology or/and normal), calibration, and
standards based on 100 analyses.
†Cost for 100 collection tubes containing heparin.
‡Salary for laboratory personnel (for specimen collection) and for technical service, based on
100 analyses.
§Sum of all previously mentioned costs.
¶Marker is on the Republic Institute for Health Insurance price list, and the cost covers test
reagents, collection tubes, personnel costs, and fee for technical service.
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MedCalc for Windows version 9.6.3 (Mariakerke, Belgium). The
minimal statistical signiﬁcance was set at P < 0.05.
For cost-effectiveness analysis, TreeAge Module Healthcare
version 1.5.2 (TreeAge Software, Inc., Williamstown, MA) was
used. To examine the robustness of the results, we performed two
types of sensitivity analysis. One-way sensitivity analysis was
performed by varying the total cost within the 30% interval
and effectiveness in the AUC within the 95% conﬁdence interval
(CI). Two-way sensitivity analysis was performed by simulta-
neously varying the total costs and effectiveness within the same
intervals [33].
Results
The accuracy of all the models was assessed by calculating their
AUC values and is presented in Table 2. The best-case model
(consisting of FRS, SOD, and O2-) had outstanding discrimina-
tive ability with an AUC value of 0.924. Only one other strategy
(FRS plus SOD) had an outstanding AUC value (0.906). All other
comparative strategies had excellent discriminative abilities
(AUC values between 0.854 and 0.887). Diagnostic models with
outstanding discriminative abilities (AUC higher than 0.9) can be
interpreted as models that have a probability greater than 90%
for correct classiﬁcation of patients. FRS accuracy was 85.4%
(AUC = 0.854), and newly deﬁned diagnostic models (best-case
and FRS plus SOD models) had better probabilities for patient
classiﬁcations.
Table 2 shows the internal validation results in which the
jackknife method was used. The jackknifed coefﬁcients implied
that there was little overexpression in the estimated predictive
accuracy of the baseline model, FRS and SH model, and FRS and
Lp(a) model. The performance of the remaining models showed
little improvement after internal validation. The results obtained
using the jackknife technique indicate that our original model
estimates were stable and were not affected by inﬂuential outlier
cases within the study sample.
Table 3 shows cost-effectiveness of risk assessment markers
for 100 CAD patients (100 analyses). The cost-effectiveness ratio
varied between €593 per AUC for the baseline model and €2425
for FRS plus apo(a) isoform. A strategy of combined FRS plus
MDA evaluation was dominated (higher costs and worse effec-
tiveness) by FRS plus O2- evaluation. The best-case model was
dominant (lower costs and better effectiveness) compared with
all markers that are on the RIHI price list. Of the remaining ﬁve
strategies, evaluation of FRS plus SH groups and FRS plus O2-
evaluation were excluded because of extended (or weak) domi-
Table 2 The results of ROC analysis and jackknife method for discriminating CAD (+) from CAD (–) patients
Strategy
AUC
(conﬁdence interval)
Standard
error‡
Jackknifed coefﬁcients
(conﬁdence interval)
FRS model* 0.854 (0.813–0.896) 0.021 0.824§ (0.780–0.861)
FRS model plus SH 0.858 (0.802–0.915) 0.029 0.826* (0.760–0.893)
FRS model plus O2- 0.875 (0.836–0.914) 0.020 0.891§ (0.837–0.945)
FRS model plus MDA 0.854 (0.810–0.898) 0.021 0.876§ (0.824–0.927)
FRS model plus SOD 0.906 (0.871–0.914) 0.018 0.939§ (0.864–1.014)
Best-case model† 0.924 (0.894–0.955) 0.015 0.947§ (0.909–0.986)
FRS model plus Lp(a) 0.853 (0.818–0.896) 0.022 0.852§ (0.802–0.902)
FRS model plus apoB 0.855 (0.814–0.896) 0.021 0.880§ (0.834–0.925)
FRS model plus apoA-I 0.858 (0.817–0.899) 0.021 0.875§ (0.827–0.923)
FRS model plus hs-CRP 0.887 (0.839–0.915) 0.019 0.892§ (0.846–0.935)
FRS model plus apo(a) isoform 0.866 (0.824–0.907) 0.021 0.880§ (0.833–0.927)
*Framingham risk score (FRS): gender, age, total cholesterol, triglyceride, high-density lipoprotein cholesterol, calculation of low-density lipoprotein cholesterol, systolic blood pressure, treatment
for hypertension, and cigarette smoking. Best-case model: FRS, SOD, and O2-.
†Best-case model: FRS plus SOD and O2-.
‡Standard error for AUC.
§A jackknifed coefﬁcient was stable because its calculated t values exceed the t critical value.
ROC, receiver operating characteristic; CAD, coronary artery disease;AUC, area under the curve; SH, sulfhydryl; O2-, superoxide anion; MDA, malondialdehyde; SOD, superoxide dismutase;
Lp(a), lipoprotein (a); apoB, apolipoprotein B; apoA-I, apolipoprotein A-1; hs-CRP, high-sensitivity C-reactive protein.
Table 3 Costs, effectiveness, and incremental cost-effectiveness for a model for CAD prediction based on 100 analyses
Strategy Cost (€)
Incremental
cost (€)
Effectiveness
(AUC)
Incremental
effectiveness (AUC)
C/E
(€/AUC) ICER (€/AUC)
FRS model* 506.7 — 0.854 — 593 —
FRS model plus SH 543.4 36.7 0.858 0.004 633 9167
FRS model plus O2- 558.5 15.1 0.875 0.017 638 885
FRS model plus MDA 568.0 9.5 0.854 -0.021 665 Dominated
FRS model plus SOD 570.5 12.1 0.906 0.031 630 389
Best-case model† 622.2 51.7 0.924 0.018 673 2873
FRS model plus lipoprotein (a) 767.1 144.8 0.854 -0.070 899 Dominated
FRS model plus apolipoprotein B 1020.9 398.7 0.855 -0.069 1194 Dominated
FRS model plus apolipoprotein A-I 1035.0 412.7 0.858 -0.066 1206 Dominated
FRS model plus CRP 1139.4 517.2 0.887 -0.037 1285 Dominated
FRS model plus apolipoprotein (a) isoform 1261.3 639.0 0.866 -0.058 1456 Dominated
*FRS model: gender, age, total cholesterol, triglyceride, high-density lipoprotein cholesterol, calculation of low-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension,
and cigarette smoking.
†Best-case model: FRS plus SOD and O2-.
Dominated strategy: strategy with higher cost and lower effectiveness than another strategy (second best).
CAD, coronary artery disease; FRS, Framingham risk score; SH, sulfhydryl; O2-, superoxide anion; MDA, malondialdehyde; SOD, superoxide dismutase; CRP, C-reactive protein;AUC, area under
the curve; ICER, incremental cost-effectiveness ratio.
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nance, meaning that both strategies were dominated by a linear
combination of baseline models and FRS plus SOD evaluation.
The ICER calculation for the remaining three strategies: base-
line, FRS plus SOD evaluation, and the best-case model, is pre-
sented in Table 4. For the FRS plus SOD, the ICER (compared
with the baseline model) was €1227 per additional accuracy
calculated for 100 analyses. The ICER for the best-case model
(compared with the baseline model) was €1650 per additional
accuracy calculated for 100 analyses.
The efﬁciency frontier composed of strategies that had the
lowest cost and the highest effectiveness available is presented in
Figure 2. It consists of three strategies (the baseline model, FRS
plus SOD evaluation, and the best-case model) with costs that
ranged from €506 to €622 per 100 analyses. All other strategies
lie on the left and above the frontier, indicating that the costs of
these strategies was higher and accuracy was lower compared
with strategies on the frontier.
Sensitivity analysis indicated that results were robust. The
costs of diagnostic markers have greater potential effects on
results compared with the same marker effectiveness. Only the
costs of FRS, SOD, O2-, SH groups, and MDA posed a potential
to inﬂuence results. Sensitivity analyses using the different cost
values (within the 30% range) for these variables showed a
range of €585.6 to €1594.5 per AUC gained for the FRS and
SOD model. The cost of FRS was identiﬁed as the most sensitive
variable, and it represented part of the cost of all other models.
Therefore, it was not reasonable to expect a signiﬁcant change in
the results.
Discussion
We have analyzed the cost-effectiveness of selected CAD labora-
tory markers from a third-party payer perspective. One of the
tools for identiﬁcation of individuals at high risk for coronary
events is the FRS that has been used for the creation of the
baseline model for our study. The FRS has serious limitations
[19,20], which can be overcome using population-adjusted equa-
tions or by a multimarker approach. In our study, the effective-
ness of each model was estimated by AUC calculations after
construction of ROC curves, which are valuable tools for the
assessment of diagnostic accuracy of laboratory tests [34]. A
multimarker approach enhances risk stratiﬁcation of patients
and adds to the overall prediction of risk based on the FRS
[16,17]. The AUC of the baseline model was among the lowest
AUC values when compared with other models tested (Table 2).
This is in agreement with results from other studies regarding the
accuracy of the FRS (AUC values vary between 0.640 and 0.813)
[35–37]. In our study, only two strategies showed outstanding
discriminative abilities: the model consisting of FRS plus SOD
and the best-case model (FRS, SOD plus O2-), with AUC values
Table 4 Costs, effectiveness, and incremental cost-effectiveness for CAD laboratory markers after elimination of dominant strategies based on 100
analyses
Strategy Cost (€)
Incremental
cost (€)
Effectiveness
(AUC)
Incremental
effectiveness (AUC)
C/E
(€/AUC)
ICER
(€/AUC)
FRS model* 506.7 — 0.854 — 593 —
FRS model plus SOD 570.5 63.8 0.906 0.052 630 1227
Best-case model† 622.2 51.7 0.924 0.018 673 2873
*FRS model: gender, age, total cholesterol, triglycerides, high-density lipoprotein cholesterol, calculation of low-density lipoprotein cholesterol, systolic blood pressure, treatment for
hypertension, and cigarette smoking.
†Best-case model: FRS, SOD, and O2-.
CAD, coronary artery disease; SOD, superoxide dismutase;AUC, area under the curve; ICER, incremental cost-effectiveness ratio; FRS, Framingham risk score.
Figure 2 Efﬁciency frontier of the models for coronary artery disease risk assessment. Framingham risk score (FRS): gender, age, total cholesterol, triglycerides,
high-density lipoprotein cholesterol, calculation of low-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, and cigarette smoking.
Best-case model: FRS, superoxide dismutase (SOD), and superoxide anion (O2-).All models were constructed by the addition of one laboratory marker to the FRS,
except the best-case model, which was determined from the logistic regression analysis. AUC, area under the curve; apo(a), apolipoprotein (a) isoform; Lp(a),
lipoprotein (a); apoA-I, apolipoprotein A-I; apoB, apolipoprotein B; MDA, malondialdehyde; hs-CRP, high-sensitivity C-reactive protein; SH, sulfhydryl.
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of 0.906 and 0.924, respectively (Table 2). This ﬁnding implies
that the addition of oxidative stress/antioxidative defense
markers to traditional cardiovascular risk factors provides
enhanced overall predictive power and is consistent with our
earlier observations [38,39]. According to our results, the addi-
tion of lipid markers to the FRS did not improve patient strati-
ﬁcation (Table 2). The accuracies of the model consisting of FRS
plus SOD and the best-case model were similar to the accuracy of
quantitative computed tomography (CT) angiography (AUC of
0.93 [95% CI 0.9–0.9]) for detecting or ruling out stenoses
50% [40].
Desirable features of biomarkers depend on their intended use
(screening, diagnostic, or treatment biomarkers), whereas cost-
effectiveness is an important feature for all of them [41]. Economic
evaluation of lipid and/or inﬂammatory markers has been per-
formed in a limited number of studies [21–23,37]. Nevertheless,
cost-effectiveness analysis of oxidative stress and antioxidative
markers has not been published. To our knowledge, this is the ﬁrst
study that has incorporated lipid, inﬂammatory, and markers of
oxidative stress and the oxidative system, their diagnostic accura-
cies, and economic considerations for CAD risk evaluation.
Our study suggests that evaluation of the FRS plus SOD was
the most cost-effective model for CAD prediction (Table 3). The
model provides additional diagnostic accuracy (increase in
AUC) compared with current risk assessment based on the FRS.
The cost (just €63.78 for 100 analyses) makes it suitable for
laboratory use. Additional costs per gained diagnostic accuracy
would be €1227/AUC for 100 analyses compared with conven-
tional risk assessment based solely on the FRS (Table 4). The
combined determination of FRS, SOD, and O2- (the best-case
model) provided better diagnostic accuracy with an AUC value
of 0.924 and an extra cost of €52 per 100 analyses. Ridker and
colleagues [42,43] showed that the addition of hs-CRP determi-
nation signiﬁcantly improved clinical prediction of the models
based on lipids alone, which is in agreement with our ﬁnding
that the model that included FRS and hs-CRP had greater accu-
racy compared with the baseline model (Table 2). Nevertheless,
the model was not found to be cost-effective (Table 3). In con-
trast, Blake and coworkers [22] noted that a strategy involving
hs-CRP could be relatively cost-effective in middle-aged patients
without overt hyperlipidemia. In addition, economic evaluations
conducted in Germany and Italy showed that hs-CRP was a
cost-effective marker, and it improved increased cardiovascular
risk prediction, especially among individuals aged 45 years and
older, and it improved the effectiveness of currently available
therapies by selecting patients at higher risk [21]. Schnell-
Inderst et al.’s study evaluated risk prediction models after
adding hs-CRP to traditional risk factors. Adding hs-CRP to the
prediction models increased AUC by up to 0.027, but both the
clinical relevance and cost-effectiveness of this improvement
remain unclear [37]. Such differences could be explained by
different study designs. Our study explored cost-effectiveness of
different models in terms of their abilities to predict CAD. In
contrast, improved outcomes and reduced costs of cardiovascu-
lar events and statin therapy have also been considered in the
other aforementioned studies.
Bearing in mind that the estimated direct costs of heart
disease in the United States in 2009 most likely reached
US$106.3 billion (representing cost per capita of US$347) [44]
and that in the EU in 2006, the cost of CAD was just under €24
billion (representing cost per capita of €49) [45], possible savings
in CAD diagnostics and therapy could be made. According to a
cost-effectiveness study of coronary CT angiography, the ICER
was US$17,516 per correct diagnosis [46]. Our model that incor-
porated laboratory markers had a lower ICER value, but as the
outcomes were not expressed in the same units, we could not
make suitable comparisons between the two studies.
Our ROC curve results reﬂected the ability of the examined
models to discriminate between CAD cases and CAD-free sub-
jects. Therefore, the results permitted us to evaluate the usefulness
of models as screening tools for clinically signiﬁcant CAD. To
assess the predictive value of models as diagnostic tools, patients
presenting with similar symptoms but without any angiographi-
cally visible stenoses should be a control group rather than
apparently healthy CAD-free subjects. Nevertheless, as coronary
angiography is an aggressive method, it is never performed
without good reason. Accordingly, it was not possible for us to
recruit a sufﬁcient number of patientswith 0% stenosis thatwould
have allowed us to perform meaningful statistical analyses.
The oxidative stress/antioxidative defense markers included
in this study do not have deﬁned thresholds (cutoff values), and
they have not generally been included in routine laboratory
analysis. Prospective studies including a large number of subjects
are needed to elucidate the accuracy of the oxidative stress/
antioxidative defense markers in terms of test sensitivity and
speciﬁcity, likelihood ratios, and predictive values, and to assess
their cost-effectiveness in clinically more informative measures
[47]. The best diagnostic model for response to therapy still
remains to be conclusively identiﬁed. Nevertheless, our study has
illustrated that the use of AUC analysis and ICER enables
decision-makers to choose a model among different diagnostic
models with similar diagnostic importance but with different
associated costs. Diagnostic models with outstanding discrimi-
native function (AUC > 0.9) had probability >90% for correct
classiﬁcation of disease. From a diagnostic point of view, if a
diagnostic model has better accuracy, it has a higher probability
for early CAD diagnosis. This would be very important for better
identiﬁcation of individuals with CAD risk and immediate thera-
peutic intervention, which would save future health-care cost
expenditure. In addition, the inclusion of other laboratory
markers (including N-terminal pro-brain natriuretic peptide,
brain natriuretic peptide, total oxidative stress status, total anti-
oxidant status, pro-oxidative–antioxidative balance, and soluble
tumor necrosis factor-like weak inducer of apoptosis [sTWEAK])
would add strength to the CAD prediction model.
The power of our data analysis was limited by study sample
size. We used the c statistic for discrimination ability and the
jackknife method for internal validation because there were no
other similar data for us to validate our models. There is a
general demand for further research aimed at probabilistic,
instead of discriminating, analysis to evaluate diagnostic models
with biomarkers and risk factors that can also be applied easily
by clinicians and interpreted in a meaningful way.
It should be noted that markers on the RIHI price list levy
service fees, whereas for markers that are not on the list, we
determined service fees as the sum of time needed for sample and
test preparation, and for automatic or manual evaluation of the
100 samples. Finally, our study incorporated only direct medical
costs as the study perspective was that of a third-party payer. We
did not take into account costs for equipment/analyzers for
marker evaluation because we assumed that the clinical labora-
tory already had adequate analyzers. In the case of a different
scenario, the included costs and results would differ substantially.
We can make suitable comparisons with other studies that noted
the cost of hs-CRP. In our study, the calculated cost for hs-CRP
was €6.32 per patient. The cost to measure C-reactive protein per
patient in Italy and Germany was €3.8 and €7.5, respectively
[21], whereas the cost in the United States was €18 (US$25) [22].
In conclusion, our results support the feasibility of using
additional biomarkers (especially the FRS plus SOD model) in
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CAD screening. In times of sparing economic resources, the
introduction of oxidative stress/antioxidative defense markers
into the clinical laboratory would be highly convenient because
they are easy to perform and do not require dedicated personnel
and equipment. Prospective studies validating the beneﬁt of oxi-
dative stress/antioxidative defense, inﬂammatory, and lipid
markers in combination with traditional markers to fully deter-
mine the most cost-effective strategy for coronary risk assessment
are currently lacking.
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